ArticleFrontiers in oncology2025
Predicting resectability after neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer: a single center, retrospective trial.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Objectives: Pancreatic ductal adeno carcinoma (PDAC) in its borderline resectable (BR) stage often limits the possibility of complete resection, currently the only potential path to a cure. Neoadjuvant chemotherapy seeks to downsize tumors, thereby increasing the chances of achieving an R0 resection. However, accurately predicting resectability following such treatment remains challenging. This study aims to identify and evaluate potential biomarkers that may improve preoperative assessment of tumor resectability during exploratory laparotomy, thereby minimizing the incidence of futile surgical interventions and their associated morbidity in patients with non-resectable malignancies. Methods: We conducted a retrospective analysis of all patients who underwent exploratory laparotomy following neoadjuvant chemotherapy at the Department of Visceral, Thoracic, and Vascular Surgery, University Hospital Dresden, between 2011 and 2022. Employing a propensity score matching, we compared patients with resectable and unresectable pancreatic cancer. The primary endpoint was to evaluate preoperative parameters for predicting resectability status. Results: This study included initially 134 patients with neoadjuvant treated BR PDAC who underwent exploratory laparotomy. Among them, 100 (74.6%) underwent curative intended resection, and 34 (25.4%) had an explorative laparotomy only. After Propensity Score Matching we found that a pre-chemotherapy CA 19-9 Value < 450 U/ml (OR 2.9; 95% CI: 1.04 - 8.53, p = 0.04), a pre-operative CA19-9 value of < 105 U/ml (OR 13.9; 95% CI: 3.88 - 49.7, p = 0.001), and a pre - to post-chemotherapy CA19-9 ratio of ≤ 15% (OR 9; 95% CI: 2.48 - 32.7, p = 0.001) raised the odds for resectability. Further, if the combination of a preoperative CA 19-9 < 105 U/ml and a pre - to post-chemotherapy CA19-9 ratio of < 15% was present, the resectability rate increased up to 93%, compared to 30% when both parameters were above the threshold. This specific constellation was a significant predictor (OR 63; 95% CI: 7.84 - 506, p = 0.001) for curative resectability. Conclusions: Our data highlight not only the significant role of the preoperative CA19-9 value and the pre- to post-chemotherapy CA19-9 ratio but, even more importantly, emphasize the critical impact of the combination of these two parameters on the resectability of BR-PDAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.